Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study

Citations of this article
Mendeley users who have this article in their library.
Get full text


Background. Interferon-α has been successfully used for induction of remission in patients with Churg-Strauss syndrome, but data on its ability to prevent relapses and its safety during long-term use are lacking. Objective. To examine the safety and efficacy of interferon-α for maintenance of remission in Churg-Strauss syndrome. Patients and methods. In a prospective open-label long-term observational study, 13 patients with CSS in stable remission received interferon-a (3x3 Mio. I.U/week s.c.)for maintenance of remission. Primary end point was the incidence of relapses. Secondary end points were the doses of concomitant prednisolone and the frequency adverse events. Results. After a median follow up of 64 month three patients were still on treatment with interferon-α all with a dose of 9 million units/week. In nine patients, interferon-α was discontinued for lack of efficacy (n=5), due to adverse events (n=2), or both (n-2) after median of 63 months (15-153) of therapy. A total of 3 major and 18 minor relapses occurred in 10 of the 13 patients with a median time to first relapse of 17 months (range 5-46). Sera of relapsing patients did not contain antibodies against interferon-α. In 6 relapsing patients treatment was switched to cyclophosphamide (n=4) or methotrexate (n-2). Four episodes of worsened asthmatic symptoms associated with a mild rise of blood eosinophils occurred in 3 patients and resolved following a transient increase of the oral prednisolone dosage. After 49 months one patient died probably due to a relapse. IFN-α was ceased prematurely, because of autoimmune-thyreoiditis in one, depression in another and cerebral leukoencephalopathy in two patients. Overall, 18 infectious episodes with need of antimicrobial treatment were observed. Conclusion. Recombinant interferon-α appears to be partially effective in the prevention of major relapses in patients with Churg-Strauss syndrome. Due to numerous side effects and infections during long-term administration its use should be restricted to patients with contraindications against conventional immunosuppressive therapies. © Copyright Clinical and Experimental Rheumatology 2010.




Metzler, C., Csernok, E., Gross, W. L., & Hellmich, B. (2010). Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study. Clinical and Experimental Rheumatology, 28(1 SUPPL. 57).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free